Contributions of SETD2 mutations in clear cell renal cell carcinoma (ccRCC)
Contributions of SETD2 mutations in clear cell renal cell carcinoma (ccRCC)
批准号:
10395442
负责人:
Shilpa Dhar
金额:
$3.73万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-04-16 至 2025-04-15
关键词:
AffectBiochemicalBiological AssayCRISPR/Cas technologyCancer BiologyCancer PatientCell LineCellsCellular AssayCellular MorphologyChIP-seqCharacteristicsChromatinClear cell renal cell carcinomaClinicalCollaborationsComplexDNA MethylationDataDepositionDevelopmentDiagnosisDisciplineDiseaseDisease remissionDisease-Free SurvivalEnvironmentEpigenetic ProcessFellowshipFosteringFoundationsFunctional disorderGenetic TranscriptionGenomic InstabilityGenotypeGoalsHistone-Lysine N-MethyltransferaseHistonesIntercistronic RegionKidney NeoplasmsLaboratoriesLeadLengthLinkLiteratureLocationLysineMalignant NeoplasmsMediatingMethyltransferaseMissense MutationModelingMolecularMutateMutationOutcomeOwnershipPatientsPeptide FragmentsPharmacotherapyPhysiologicalPlayPrecision therapeuticsProcessPrognosisProtein FragmentProteinsRNA Polymerase IIRadiation therapyRenal carcinomaReproductive BiologyResearchResistanceRoleS-AdenosylhomocysteineSET DomainScientistShapesSystemThe Cancer Genome AtlasTherapeuticTrainingTranscriptUnited Statesamino groupbasecancer subtypeschemotherapychromatin immunoprecipitationclinically relevantcohortexperimental studygrasphistone modificationimprovedinsightknock-downloss of functionmethyl groupmultidisciplinarymutantnovel therapeuticspatient derived xenograft modelprotein structurerepairedresponsetherapeutic developmenttumortumorigenesiswound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Cancer epigenetics has driven a surge of research in recent years as several chromatin-
associated factors have been identified in the process of tumorigenesis. A critical chromatin-
modifying protein involved in active transcription, SETD2, has been found to be mutated in
approximately 15% of clear cell renal cell carcinomas (ccRCCs). ccRCC patients have shown
resistance to both chemotherapy and conventional radiation therapies, and although major
therapeutic advances have been made, only a fraction of patients shows durable clinical
responses and long-term remission; thus, there is an urgent need for novel therapies in the field.
Typically, SETD2 mutations are grouped as functionally identical; however, they can be
grouped according to their structural or enzymatic characteristics. This project seeks to answer
the question of how the loss of SETD2 protein is molecularly distinct from loss of its enzymatic
activities. The first aim will use ChIP-seq and biochemical studies to determine the relationship
between SETD2 mutation and differential chromatin dysregulation and to elucidate the particular
mechanism in which another protein or peptide fragment acts aberrantly in the absence of SETD2.
The second aim will use ChIP-seq and cellular studies to determine how distinct molecular
mechanisms of SETD2 mutations in the context of ccRCC results in differential ccRCC
development and progression.
The multi-disciplinary environment in the Banaszynski laboratory fosters collaboration
amongst diverse scientists and trainees benefit from the guidance of Dr. Banaszynski and
established scientists in the Green Center for Reproductive Biology. By the end of this training
fellowship period, I will accomplish four goals, I will : 1) become a disciplined experimentalist, 2)
gain ownership of my data, 3) grasp a thorough understanding of the foundational and current
literature that shapes the field of cancer biology, and 4) be an effective scientific communicator
and leader.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Contributions of SETD2 mutations in clear cell renal cell carcinoma (ccRCC)
-
批准号:10596500
-
项目类别:
-
资助金额:$3.82万
-
财政年份:2021
-
负责人:Shilpa Dhar
-
依托单位:
海外基金